INNOVUS PHARMACEUTICALS, INC. - FORM 10-K - EX-23.1 - CONSENT OF EISNERAMPER LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM. - March 31, 2015

Attached files

file filename
EX-31.2 - CERTIFICATION OF THE REGISTRANT?S PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15(D)-14(A). - INNOVUS PHARMACEUTICALS, INC.ex31-2.htm
EX-21.1 - LIST OF SUBSIDIARIES - INNOVUS PHARMACEUTICALS, INC.ex21-1.htm
EX-31.1 - CERTIFICATION OF THE REGISTRANT?S PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULES 13A-14(A) AND 15(D)-14(A), AS ADOPTED - INNOVUS PHARMACEUTICALS, INC.ex31-1.htm
EX-14.1 - CODE OF ETHICS. - INNOVUS PHARMACEUTICALS, INC.ex14-1.htm
EX-10.24 - OFFER LETTER, DATED FEBRUARY 6, 2014, BETWEEN INNOVUS PHARMACEUTICALS, INC. AND LYNNETTE DILLEN. - INNOVUS PHARMACEUTICALS, INC.ex10-24.htm
EXCEL - IDEA: XBRL DOCUMENT - INNOVUS PHARMACEUTICALS, INC.Financial_Report.xls
10-K - FORM 10-K - INNOVUS PHARMACEUTICALS, INC.innv10k_dec312014.htm
EX-32.1 - CERTIFICATION OF THE REGISTRANT?S PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SS. 1350, AS ADOPTED PURSUANT - INNOVUS PHARMACEUTICALS, INC.ex32-1.htm
Exhibit 23.1
 
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
 
We consent to the incorporation by reference in the Registration Statement of Innovus Pharmaceuticals, Inc. (the “Company”) on Form S-8 (No. 333-186725-13620840), pertaining to the Company’s Incentive Stock Option Plan, Nonstatutory Stock Option Agreement, and the Company’s Equity Incentive Plan, and the Registration Statement of Innovus Pharmaceuticals, Inc. on Form S-8 ( No. 333-201352), pertaining to the Company’s registration of shares of the Company’s 2014 Equity Incentive Plan of our report dated March 31, 2015, on our audits of the consolidated financial statements as of December 31, 2014 and 2013, and for each of the years in the two-year period ended December 31, 2014,which report is included in the Annual Report on Form 10-K filed on March 31, 2015. Our report includes an emphasis-of-matter paragraph highlighting the line of credit provided by the President and Chief Executive Office of the Company, and deferral of the payment of his salary.
 
/S/ EISNER AMPER LLP
 
Iselin, New Jersey
 
March 31, 2015

INNOVUS PHARMACEUTICALS, INC. Reports